General presentation of Cellectis
Cellectis is a French company specializing in clinical-stage biopharmaceuticals. More specifically, it specializes in the development of a new generation of immunotherapy treatments to fight cancer based on unequal CAR-T cells or UCART.
Cellectis is a fairly old company in this sector, having been active in the field of genome engineering for more than 18 years. In particular, it has the THALEN genome editing technology and an innovative electroporation technology called PulseAgile. With its experience, know-how and technology, Cellectis is looking for a way to eliminate cancer cells using the patient's immune system.
Cellectis is a pioneer in genome research applied to life sciences and its main goal is to create innovative treatments to treat different diseases and therefore applicable to several markets.
In addition to knowing the detailed activities of the Cellectis group, you should also know the different subsidiaries of this company and their specialties. This will help you to better analyze the elements that can influence the price of this stock in a more or less strong way. Here are the two main subsidiaries of Cellectis at the moment.
- The Calyxt subsidiary, formerly known as Cellectis Plant Sciences, is based in Minnesota and more precisely in New Brighton, USA. It is specialized in the development of healthier food products. To achieve this goal, Calyxt has developed a platform to improve the agronomic value and quality of crops for the world's agricultural and food industries.
- The second subsidiary of the Cellectis group that you should know about is Cellectis Inc, also based in the United States but this time in New York. This subsidiary is specialized in the development of innovative programs using T lymphocytes armed with a CAR targeting certain types of cancers.
68% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro